Articles related to CLINICAL TRIALS

The recent LODESTAR clinical trial has revealed that although the two statins are equally effective in preventing heart attacks, strokes, and death, one has been associated with a higher risk of developing type 2 diabetes and requiring cataract surgery.

The advent of zuranolone may be going beyond postpartum depression, with 87.5% of patients noticing improvements within the first week of treatment for MDD.

The future of advanced bladder cancer treatment has been crystallized by the findings of the EV302 study, which demonstrated a median overall survival of 31.5 months with enfortumab vedotin-ejfv plus pembrolizumab.

The GCIG INTERLACE study has demonstrated a significant improvement in 5-year survival rates in advanced cervical cancer, from 72% to 80%, with the addition of induction chemotherapy to standard-of-care chemoradiation.

The recent study on FLT3 inhibitor monotherapy brings hope to the field of oncology, particularly for patients with high-risk FLT3-mutated AML. Administered at the stage of molecular failure, the therapy has shown encouraging survival rates.

This review encompasses nine recent studies in oncology, highlighting the application of innovative therapies and drug combinations in the treatment of lung cancer.